Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics to Report Q1 Earnings: Is a Beat in the Cards?
CRSP eyes a Q1 beat as rising Casgevy uptake, improving sales outlook and a strong Earnings ESP set the stage ahead of results.
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $56.42, indicating a +1.58% shift from the previous trading day.
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?
CRISPR Therapeutics plans to post clinical trial updates for multiple candidates this year. The company's stock could jump if it can impress the market.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $55.72, marking a -1.83% move from the previous day.
CRISPR Therapeutics AG (CRSP) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
CRISPR Therapeutics AG (CRSP) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Personalized Biotech Flywheel Cathie Wood Built Is Still a Winning Bet Today
What if the biggest winners in biotech weren't the ones promising miracle cures, but the ones quietly supplying the picks and shovels — data that makes those cures possible?
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.51, moving +1.43% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $48.81, denoting a +2.61% move from the preceding trading day.
A Turning Point For Crispr Therapeutics As Commercial Growth Accelerates
CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a robust pipeline. CASGEVY's increasing patient initiations and revenue growth provide a near-term path to profitability, with a strong foundation for future expansion. CRSP's in vivo cardiovascular pipeline, notably CTX310 and CTX320/321, targets large, underserved markets with disruptive one-time gene therapies.
I Expect Crispr Therapeutics To Break Out As 2026 Revenue Exceeds Expectations
Crispr Therapeutics AG is positioned for a revenue inflection as Casgevy ramps in 2026, following earlier FDA/EMA approvals for SCD and TDT. Analysts are underestimating the Casgevy revenue ramp. CRSP now trades at the low end of its 4-year range, despite risk mitigation, a very promising pipeline, and a robust balance sheet, creating a compelling entry point. Casgevy's efficacy is very strong, with >90% response rates, but uptake has lagged due to burdensome preconditioning and patient concerns.
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.09, moving +1.42% from the previous trading session.
